In the latest episode of Boardroom Talk, Harriet Clarfelt talks to Stephen O'Hara, founder and chief executive of OptiBiotix. The group has enjoyed decent share price growth in recent months thanks to excitement surrounding microbiome modulation - where OptiBiotix is among the UK's most innovative researchers. But Harriet questions whether that is sustainable in the absence of any sales forecasts and the uncertainty surrounding its product development.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.